C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept

Buch, Maya H; Seto, Yohei; Bingham, Sarah; Bejarano, Victoria; Bryer, Domini; White, Jonathan; Emery, Paul

doi:10.1002/art.20711

Cited by 100 publications

(68 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we were unable to draw a definitive conclusion in this study, and additional studies with a larger number of samples should be performed to confirm our observations and speculations. In a recent study, it was shown that failure to suppress serum CRP at week 2 of therapy identified the majority of patients who were nonresponders by week 12 (47). However, in our series of patients, we did not find a significant relationship between a reduction in the CRP level at week 2 and the efficacy of infliximab at week 54.…”

Section: Discussioncontrasting

confidence: 88%

Effects of infliximab therapy on gene expression levels of tumor necrosis factor α, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis

Sugihara¹,

Tsutsumi²,

Suzuki³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Tristetraprolin (TTP), T cell intracellular antigen 1 (TIA-1), and Hu antigen R (HuR) are adenine/uridine-rich element binding proteins (ABPs) that affect the production of tumor necrosis factor ␣ (TNF␣) by binding to TNF messenger RNA (mRNA). TTP promotes deadenylation, TIA-1 inhibits translation, and HuR stabilizes TNF␣ mRNA. The aims of this study were to understand the posttranscriptional control of TNF␣ production in patients with rheumatoid arthritis (RA), and to identify parameters that may predict the efficacy of anti-TNF␣ therapy.Methods. Peripheral blood mononuclear cells from 38 patients with RA were obtained before therapy and 2 weeks and 54 weeks after administration of the first dose of infliximab, and from 20 healthy control subjects. TNF␣, TTP, TIA-1, and HuR gene expression levels were analyzed by real-time polymerase chain reaction.Results. At baseline, TTP and HuR gene expression levels, as well as the TTP:TNF␣, TTP:HuR, and TIA-1:TNF␣ gene expression ratios were lower in patients with RA than in control subjects, while expression of TNF␣, TIA-1, and TIA-1:HuR was higher in patients with RA. The TTP:HuR expression ratio decreased significantly after administration of infliximab. Positive correlations were observed between TNF␣ and TTP, TNF␣ and TIA-1, TIA-1 and HuR, and TNF␣ and HuR gene expression in both healthy control subjects and patients with RA. At baseline, the TIA-1:HuR ratio tended to be higher in patients who achieved 50% improvement according to the American College of Rheumatology criteria (ACR50) at week 54 than in those who did not achieve at least an ACR20 response.Conclusion. Differences in ABP gene expression may affect TNF␣ gene expression. A higher TIA-1:HuR expression ratio might correlate with the response to infliximab therapy.

show abstract

Section: Discussioncontrasting

confidence: 88%

Effects of infliximab therapy on gene expression levels of tumor necrosis factor α, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis

Sugihara¹,

Tsutsumi²,

Suzuki³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…In the studies by Buch et al 99 and Bingham et al 104 lack of efficacy was the primary reason for switching to ETN. In studies by Haraoui et al, 98 Cohen et al 100 and Buch et al 101 patients discontinued IFX owing to a lack of efficacy or safety.…”

Section: Etanerceptmentioning

confidence: 99%

“…Seven uncontrolled observational studies [98][99][100][101][102][103][104] were identified that assessed efficacy of ETN.…”

Section: Etanerceptmentioning

confidence: 99%

“…no need for hospital visit to receive infusion). Two studies 99,101 were carried out at the same centre (Leeds Teaching Hospitals) in the UK. These studies were described separately in this section although it is possible that patients included in Buch et al 2005 99 were a subgroup of the cohort included in Buch et al 2007.…”

Section: Figurementioning

confidence: 99%

“…Two studies 99,101 were carried out at the same centre (Leeds Teaching Hospitals) in the UK. These studies were described separately in this section although it is possible that patients included in Buch et al 2005 99 were a subgroup of the cohort included in Buch et al 2007. 101 The other studies were carried out in France, 100 Italy, 102 Finland 103 and the USA.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAAdalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Dr Paresh Jobanputra has participated in several technology assessments/appraisals related to rheumatoid arthritis as the clinical expert of the assessment group. He works as consultant rheumatologist in a large department of rheumatology. His department has taken part in clinical trials of etanercept, adalimumab, rituximab and tocilizumab. The department receives funding for nurses from Schering-Plough Ltd to administer infliximab to patients currently being treated with this drug. Currently he is the chief investigator of a clinical trial comparing adalimumab versus etanercept (ISRCTN95861172). He has, in the past, received support for educational purposes from Wyeth Pharmaceuticals (etanercept), Abbott (adalimumab) and Roche (rituximab). He has also been involved in an advisory board for Roche in relation to tocilizumab and rituximab, and has accept...

show abstract

Identification of synovial biomarkers of response to experimental treatment in early‐phase clinical trials in spondylarthritis

Kruithof

Rycke

Vandooren

et al. 2006

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept

Cited by 100 publications

References 12 publications

Effects of infliximab therapy on gene expression levels of tumor necrosis factor α, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis

Effects of infliximab therapy on gene expression levels of tumor necrosis factor α, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Identification of synovial biomarkers of response to experimental treatment in early‐phase clinical trials in spondylarthritis

Contact Info

Product

Resources

About